Nyxoah (CHIX:NYXHB) Asset Impairment Charge : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nyxoah Asset Impairment Charge?

Nyxoah's Asset Impairment Charge for the three months ended in Mar. 2024 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Nyxoah Asset Impairment Charge Historical Data

The historical data trend for Nyxoah's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah Asset Impairment Charge Chart

Nyxoah Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Nyxoah Quarterly Data
	Dec17	Dec18	Jun19	Dec19	Mar20	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Nyxoah Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Nyxoah Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Nyxoah's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyxoah (CHIX:NYXHB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (CHIX:NYXHb) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

NYXH:USA 5YI:Germany NYXH:Belgium

Address

Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435

Website

https://www.nyxoah.com

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Nyxoah (CHIX:NYXHB) Headlines

No Headlines